Viatris Reports $3.76 Billion in Q3 2025 Revenues, Faces Net Loss of $128.2 Million

Viatris Inc. reported total revenues of $3.76 billion for the third quarter of 2025, a slight increase from $3.75 billion in the same period last year. However, net sales showed a marginal decline, totaling $3.75 billion compared to $3.74 billion in the prior year, reflecting a decrease in base business due to divestitures and the impact of supply chain disruptions from its Indore manufacturing facility in India. The company recorded a net loss of $128.2 million for the quarter, a significant drop from net earnings of $94.8 million in the third quarter of 2024. This resulted in a diluted loss per share of $0.11, compared to earnings of $0.08 per share in the previous year.

For the nine months ending September 30, 2025, Viatris reported total revenues of $10.60 billion, down from $11.21 billion in the same period of 2024, marking a decrease of 5%. The decline in revenues was attributed to the Indore Impact, which negatively affected approximately $400 million in sales, alongside the effects of divestitures completed in 2024. The company’s gross profit for the nine-month period was $3.87 billion, with gross margins decreasing to 36% from 39% in the prior year, primarily due to the same factors impacting revenues.

Strategically, Viatris has made significant moves, including the acquisition of Aculys Pharma, which focuses on innovative treatments for neurological conditions. This acquisition, finalized on October 15, 2025, involved an upfront payment of $35 million and additional contingent payments based on regulatory and commercial milestones. Additionally, the company has been actively managing its share repurchase program, having repurchased approximately 6.8 million shares at a cost of $67.9 million during the third quarter, with a total of 86.1 million shares repurchased for about $918.3 million since the program's inception.

Operationally, Viatris has faced challenges, particularly with its Indore facility, which has been under scrutiny from the FDA, leading to an import alert affecting 11 products. The company has implemented a comprehensive remediation plan and is in regular communication with the FDA to resolve the issues. The estimated negative impact from the Indore facility on total revenues for the third quarter was approximately $100 million, and the company anticipates that the facility will be ready for reinspection in 2026.

Looking ahead, Viatris remains focused on its strategic initiatives, including expanding its product portfolio and addressing operational challenges. The company expects to continue leveraging its global footprint and extensive portfolio to meet healthcare needs while navigating the complexities of the pharmaceutical market. The management's outlook emphasizes the importance of maintaining operational efficiency and financial stability amid ongoing market conditions and regulatory scrutiny.